ANI Pharmaceuticals Inc. (ANIP)

80.80
0.20 0.25
NASDAQ : Health Technology
Prev Close 81.00
Open 81.02
Day Low/High 79.66 / 81.47
52 Wk Low/High 36.92 / 84.10
Volume 71.95K
Avg Volume 143.80K
Exchange NASDAQ
Shares Outstanding 12.04M
Market Cap 973.47M
EPS 1.30
P/E Ratio 69.66
Div & Yield N.A. (N.A)

Latest News

ANI Pharmaceuticals Announces Approval Of Vancomycin Hydrochloride For Oral Solution USP, 250mg/5ml

ANI Pharmaceuticals Announces Approval Of Vancomycin Hydrochloride For Oral Solution USP, 250mg/5ml

BAUDETTE, Minn., June 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Expands Generic Pipeline With Acquisition Of Seven Development Stage Drug Products From Coeptis Pharmaceuticals, Inc.

ANI Pharmaceuticals Expands Generic Pipeline With Acquisition Of Seven Development Stage Drug Products From Coeptis Pharmaceuticals, Inc.

BAUDETTE, Minn., June 18, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals To Present At Raymond James Life Sciences And MedTech Conference

ANI Pharmaceuticals To Present At Raymond James Life Sciences And MedTech Conference

BAUDETTE, Minn., June 12, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc.

ANIP: Insiders Vs. Shorts

ANIP: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and ANI Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 12.93 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

ANI Pharmaceuticals Reports First Quarter 2019 Results And Reaffirms Guidance

ANI Pharmaceuticals Reports First Quarter 2019 Results And Reaffirms Guidance

BAUDETTE, Minn., May 9, 2019 /PRNewswire/ -- For the first quarter 2019: Net revenues of $52.

ANI Pharmaceuticals Reaches Analyst Target Price

ANI Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of ANI Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $70.33, changing hands for $70.61/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

ANI Pharmaceuticals Schedules Conference Call To Discuss First Quarter 2019 Financial Results

ANI Pharmaceuticals Schedules Conference Call To Discuss First Quarter 2019 Financial Results

BAUDETTE, Minn., May 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Expands Injectable Portfolio With Distribution Agreement For FDA Approved Injectable Product

ANI Pharmaceuticals Expands Injectable Portfolio With Distribution Agreement For FDA Approved Injectable Product

BAUDETTE, Minn., April 15, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Reaches Analyst Target Price

ANI Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of ANI Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $70.33, changing hands for $70.54/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

ANI Pharmaceuticals Announces Two Generic Product Launches

ANI Pharmaceuticals Announces Two Generic Product Launches

BAUDETTE, Minn., March 27, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANIP, FTAI, LGCY, SSB, TERP, YPF Downgrades: ABC, GLOG, ICUI, NWS, SQM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

ANI Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For ANIP

ANI Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For ANIP

In trading on Tuesday, shares of ANI Pharmaceuticals Inc crossed above their 200 day moving average of $57.89, changing hands as high as $58.04 per share. ANI Pharmaceuticals Inc shares are currently trading up about 3% on the day.

Even Wall Street Experts Had a Tough Year in 2018

Even Wall Street Experts Had a Tough Year in 2018

Barron's big-name money managers did not pick many winners for the year.

Even the Experts Had a Tough Year in 2018

Even the Experts Had a Tough Year in 2018

Barron's big-name money managers did not pick many winners for the year.

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Notable Two Hundred Day Moving Average Cross - ANIP

Notable Two Hundred Day Moving Average Cross - ANIP

In trading on Tuesday, shares of ANI Pharmaceuticals Inc crossed below their 200 day moving average of $64.00, changing hands as low as $49.76 per share. ANI Pharmaceuticals Inc shares are currently trading off about 12.9% on the day.

Small-Caps Offer Port in Stormy Trade Seas

Small-Caps Offer Port in Stormy Trade Seas

Small-caps also should benefit from reduced corporate income taxes and strong U.S. economic growth.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

3 Biotech Stocks I Love for March (Celgene Is One of Them)

3 Biotech Stocks I Love for March (Celgene Is One of Them)

These biotech names are all great buys on dips. Notably Celgene, which is fresh off a terrible trading session.

3 Promising Biotech Stocks to Buy on Dips

3 Promising Biotech Stocks to Buy on Dips

From ANI Pharmaceuticals to T2 Biosystems, these names look good.

Three Biotech Opportunities

Three Biotech Opportunities

Celgene, ANI and T2 are seeing attractive entry points.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CXO, GOGL, LBRDA, LBRDK Downgrades: ANIP, CTB, HVT, HVT.A, MANH, MDT, MSA, PMBC, TAYD, TGH, UBP Initiations: CJ, FTI, VREX Read on to get TheStreet Quant Ratings' detailed report:

Commit To Purchase ANI Pharmaceuticals At $35, Earn 18.7% Annualized Using Options

Commit To Purchase ANI Pharmaceuticals At $35, Earn 18.7% Annualized Using Options

Investors eyeing a purchase of ANI Pharmaceuticals Inc shares, but tentative about paying the going market price of $60.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March put at the $35 strike, which has a bid at the time of this writing of 70 cents.

ANI Pharmaceuticals Reaches Analyst Target Price

ANI Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of ANI Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $66.33, changing hands for $68.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

ANIP Crosses Above Average Analyst Target

ANIP Crosses Above Average Analyst Target

In recent trading, shares of ANI Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $66.33, changing hands for $74.56/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

TheStreet Quant Rating: B- (Buy)